Compare KRUS & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRUS | QTTB |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.4M | 450.1M |
| IPO Year | 2019 | 2018 |
| Metric | KRUS | QTTB |
|---|---|---|
| Price | $34.96 | $8.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $62.88 | $39.67 |
| AVG Volume (30 Days) | 193.0K | ★ 705.1K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 79.75 | ★ 136.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $282,763,000.00 | $53,737,000.00 |
| Revenue This Year | $16.80 | N/A |
| Revenue Next Year | $17.77 | $150.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.88 | N/A |
| 52 Week Low | $29.69 | $1.91 |
| 52 Week High | $80.84 | $23.57 |
| Indicator | KRUS | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 47.25 |
| Support Level | $33.97 | $7.45 |
| Resistance Level | $41.99 | $9.16 |
| Average True Range (ATR) | 1.77 | 0.53 |
| MACD | -0.13 | 0.25 |
| Stochastic Oscillator | 47.71 | 75.16 |
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).